<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946918</url>
  </required_header>
  <id_info>
    <org_study_id>STU 022015-044</org_study_id>
    <nct_id>NCT02946918</nct_id>
  </id_info>
  <brief_title>Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy</brief_title>
  <official_title>Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akrimax Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In some patients, levothyroxine liquid gel capsules may demonstrate superior absorption than&#xD;
      the tablet option. Impaired absorption of thyroid hormone directly correlates to higher and&#xD;
      more unpredictable TSH (thyroid stimulating hormone) levels.&#xD;
&#xD;
      The investigators therefore hypothesize that following thyroidectomy for Stage I/II&#xD;
      differentiated thyroid cancer the gel capsule levothyroxine formulation will provide more&#xD;
      predictable TSH results and in turn require fewer dose adjustments to achieve optimal hormone&#xD;
      levels in the postoperative period.&#xD;
&#xD;
      The aim of this investigation is to compare the use of levothyroxine in liquid gel capsules&#xD;
      to tablet form for TSH suppression following thyroidectomy for presumed stage I/II&#xD;
      differentiated thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten patients will be randomized prior to surgery to receive levothyroxine in tablet form and&#xD;
      ten patients will be randomized to receive in gel capsule form. Both forms will be&#xD;
      encapsulated in order to allow double-blinding of the study.&#xD;
&#xD;
      The postoperative goal TSH will be between 0.1 and 0.5 mU/L (milli units per litre) in both&#xD;
      arms.&#xD;
&#xD;
      Patients will be seen at weeks 6, 12 and 18 postoperatively and have TSH and Free T4&#xD;
      measured. The primary outcome is the number of patients at each visit that are at goal range&#xD;
      TSH.&#xD;
&#xD;
      A secondary analysis will compare the dose changes required between the two groups in order&#xD;
      to achieve goal TSH.&#xD;
&#xD;
      Another secondary analysis will investigate the patients' quality of life. Two different&#xD;
      surveys (see secondary outcomes below) will be performed at both study entry and completion&#xD;
      to compare the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminating study as sponsor has sold the drug to another company&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients in Each Group at Predefined Target TSH Range at 18 Weeks</measure>
    <time_frame>18 weeks</time_frame>
    <description>The target TSH (Thyroid stimulating hormone) range will be 0.1 to 0.5 mU/L. The number of patients in each arm (gelcaps or tablets) who are in this range at the completion of the study (18 weeks) will be assessed and the data compared at completion of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Dose Adjustments</measure>
    <time_frame>18 weeks</time_frame>
    <description>The number of dose adjustments required to attain TSH target range for each formulation will be tabulated and the data compared at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Patient Quality of Life Score</measure>
    <time_frame>Baseline,18 weeks</time_frame>
    <description>Patients will be administered survey (Thyroid-Dependent Quality of Life ) to assess their quality of life (at the beginning of the study and again at study completion). The results of these scores will be tabulated and compared between the two arms. Possible score range from 0 to 450; lower score means improved quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Survey</measure>
    <time_frame>18 weeks</time_frame>
    <description>The Thyroid Treatment Satisfaction Questionnaire Measures the treatment satisfaction. Possible measure 0 to 42; Higher the score, better the outcome (more satisfied the patient)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Thyroid Cancer</condition>
  <condition>Postsurgical Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelcaps</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily</description>
    <arm_group_label>Gelcaps</arm_group_label>
    <arm_group_label>Tablets</arm_group_label>
    <other_name>Tirosint, Synthroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Presumed AJCC (American Joint Committee on Cancer) tumor Stage I or II&#xD;
&#xD;
          -  Planned total or near-total thyroidectomy&#xD;
&#xD;
          -  Planned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperatively&#xD;
&#xD;
          -  Normal serum TSH within 12 months preceding surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AJCC Stage III or greater&#xD;
&#xD;
          -  Undifferentiated, Anaplastic or Medullary Thyroid Cancer&#xD;
&#xD;
          -  Planned postoperative TSH goal other than 0.1-0.5 mU/L&#xD;
&#xD;
          -  History of gastrointestinal malabsorption or gastric bypass surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of medications that alter the absorption or metabolism of levothyroxine&#xD;
&#xD;
          -  Prior use of levothyroxine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Tessnow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vita R, Fallahi P, Antonelli A, Benvenga S. The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv. 2014 Jul;11(7):1103-11. doi: 10.1517/17425247.2014.918101. Epub 2014 Jun 4. Review.</citation>
    <PMID>24896369</PMID>
  </reference>
  <reference>
    <citation>McMillan CV, Bradley C, Woodcock A, Razvi S, Weaver JU. Design of new questionnaires to measure quality of life and treatment satisfaction in hypothyroidism. Thyroid. 2004 Nov;14(11):916-25.</citation>
    <PMID>15671770</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <results_first_submitted>November 4, 2020</results_first_submitted>
  <results_first_submitted_qc>November 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 1, 2020</results_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Alex Tessnow</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>levothyroxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02946918/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tablets</title>
          <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
        </group>
        <group group_id="P2">
          <title>Gelcaps</title>
          <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient unblinded himself</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ran out of study medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tablets</title>
          <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
        </group>
        <group group_id="B2">
          <title>Gelcaps</title>
          <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients in Each Group at Predefined Target TSH Range at 18 Weeks</title>
        <description>The target TSH (Thyroid stimulating hormone) range will be 0.1 to 0.5 mU/L. The number of patients in each arm (gelcaps or tablets) who are in this range at the completion of the study (18 weeks) will be assessed and the data compared at completion of the study.</description>
        <time_frame>18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tablets</title>
            <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Gelcaps</title>
            <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each Group at Predefined Target TSH Range at 18 Weeks</title>
          <description>The target TSH (Thyroid stimulating hormone) range will be 0.1 to 0.5 mU/L. The number of patients in each arm (gelcaps or tablets) who are in this range at the completion of the study (18 weeks) will be assessed and the data compared at completion of the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Dose Adjustments</title>
        <description>The number of dose adjustments required to attain TSH target range for each formulation will be tabulated and the data compared at the end of the study</description>
        <time_frame>18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tablets</title>
            <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Gelcaps</title>
            <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Dose Adjustments</title>
          <description>The number of dose adjustments required to attain TSH target range for each formulation will be tabulated and the data compared at the end of the study</description>
          <units>The number of dose adjustments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.63"/>
                    <measurement group_id="O2" value="1.25" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Patient Quality of Life Score</title>
        <description>Patients will be administered survey (Thyroid-Dependent Quality of Life ) to assess their quality of life (at the beginning of the study and again at study completion). The results of these scores will be tabulated and compared between the two arms. Possible score range from 0 to 450; lower score means improved quality of life.</description>
        <time_frame>Baseline,18 weeks</time_frame>
        <population>Out of 6 people from the Tablet group, 1 did not complete the second survey. Out of 8 people from the Gelcap group, 3 people did not complete the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Tablets</title>
            <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Gelcaps</title>
            <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Patient Quality of Life Score</title>
          <description>Patients will be administered survey (Thyroid-Dependent Quality of Life ) to assess their quality of life (at the beginning of the study and again at study completion). The results of these scores will be tabulated and compared between the two arms. Possible score range from 0 to 450; lower score means improved quality of life.</description>
          <population>Out of 6 people from the Tablet group, 1 did not complete the second survey. Out of 8 people from the Gelcap group, 3 people did not complete the survey.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="12.99"/>
                    <measurement group_id="O2" value="-29.6" spread="48.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Survey</title>
        <description>The Thyroid Treatment Satisfaction Questionnaire Measures the treatment satisfaction. Possible measure 0 to 42; Higher the score, better the outcome (more satisfied the patient)</description>
        <time_frame>18 weeks</time_frame>
        <population>Out of 6 people from the Tablet group, 1 did not complete the second survey. Out of 8 people from the Gelcap group, 3 people did not complete the survey.</population>
        <group_list>
          <group group_id="O1">
            <title>Tablets</title>
            <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Gelcaps</title>
            <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction Survey</title>
          <description>The Thyroid Treatment Satisfaction Questionnaire Measures the treatment satisfaction. Possible measure 0 to 42; Higher the score, better the outcome (more satisfied the patient)</description>
          <population>Out of 6 people from the Tablet group, 1 did not complete the second survey. Out of 8 people from the Gelcap group, 3 people did not complete the survey.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="3.70"/>
                    <measurement group_id="O2" value="39" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks (until completion of the study)</time_frame>
      <desc>All 14 subjects were considered at risk for adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Tablets</title>
          <description>Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
        </group>
        <group group_id="E2">
          <title>Gelcaps</title>
          <description>Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)&#xD;
Levothyroxine: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alex Tessnow-ASSOC PROFESSOR</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214/648-3685</phone>
      <email>Alex.Tessnow@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

